PharmaJet appoints Chris Cappello new CEO

Wednesday April 29, 2020 0 comments Tags: Golden, PharmaJet, Chris Cappello, Ron Lowy

GOLDEN -- PharmaJet today announced the appointment of Chris Cappello to president and CEO.PharmaJet_logoUSE 

Cappelllo replaces Ron Lowy, who was appointed executive chair of the company’s board of directors.

"In the 10 years that Chris has worked for PharmaJet, he has shown the ability to lead the organization and expand on our important collaborations with groups such as the U.S. federal government, the World Health Organization, multiple pharmaceutical partnerships, and other entities who are adopting needle-free injection systems for use around the world,” said Lowy.

“His strong business acumen, medical device expertise and established relationships are assets to the business as we move forward."

Cappello has extensive experience in medical device development and commercialization. He has spent his career managing the successful design, development, regulatory clearance and launch of both reusable and high volume disposable medical devices. 

Since joining PharmaJet, Cappello has held successive global operational leadership positions, most recently as chief operating officer. In his new role as president and CEO, he will be responsible for running all facets of the business.

Prior to joining PharmaJet, Cappello drove the development of disruptive medical device technologies at companies including AlloSource and Applied Medical. He has a Bachelor of Science degree in Mechanical Engineering from Colorado State University and a Project Management Professional certification.

"I look forward to my expanded role and am pleased to be joining the board of directors of PharmaJet,” Cappello said.

“While our needle-free injection systems are already being used extensively, there is an opportunity to expand our presence with additional strategic partnerships. Our easy-to-use needle-free systems are proven in actual large-scale field use and are applicable to the current pandemic situation as well as future global disease challenges."